ORIC Pharmaceuticals, Inc. (ORIC)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 9.52 |
| Open | 9.77 |
| Bid | 9.66 x 500 |
| Ask | 9.74 x 200 |
| Day's range | 9.50 - 10.03 |
| 52-week range | 4.90 - 16.65 |
| Volume | |
| Avg. volume | 588,590 |
| Market cap | 654.671M |
| Beta (5Y monthly) | 1.03 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
How Much Upside is Left in Oric Pharmaceuticals (ORIC)? Wall Street Analysts Think 39.3%
The mean of analysts' price targets for Oric Pharmaceuticals (ORIC) points to a 39.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- GuruFocus.com
ORIC Pharmaceuticals Inc (ORIC) Reports Q4 and Full Year 2023 Financial Results
Advances in Clinical Programs and Strengthened Cash Position Highlighted
- GuruFocus.com
ORIC Pharmaceuticals Inc CEO Jacob Chacko Sells 40,000 Shares
Jacob Chacko, the President and Chief Executive Officer of ORIC Pharmaceuticals Inc (NASDAQ:ORIC), has sold 40,000 shares of the company on March 6, 2024, according to a recent SEC Filing.
© 2024 Yahoo. All rights reserved.